Adverse drug reactions (ADRs) are a major concern in healthcare, causing significant morbidity and mortality. Pharmacogenomics offers a promising solution by identifying genetic variants associated with increased susceptibility to ADRs. By incorporating Pharmacogenomics testing into routine clinical practice, healthcare providers can identify patients at higher risk of ADRs and adjust drug selection and dosage accordingly. This personalized approach enhances patient safety and reduces the likelihood of harmful reactions. Moreover, pharmacogenomic data can contribute to the development of more targeted drug therapies, minimizing the occurrence of ADRs and improving overall treatment outcomes.